All of modern medicine is dependent on advances in chemistry and the healthcare goalposts have moved as the century has turned. We all face problems with the spreading of infectious disease on an unprecedented scale. Poorer nations struggle to afford or distribute expensive modern drugs, while in all nations drug resistance is growing. The exponentially increasing prevalence of non-infectious disease in an aging population brings unforeseen and expensive challenges to healthcare.
Often the challenges to developing better healthcare lie in a lack of basic molecular-level understanding of the disease biology, a lack of sufficiently advanced tools and methods to detect and treat disease and to validate drug targets, or a lack of an arsenal of small and large molecules to engage drug targets thereby ameliorating diseases.
These are all challenges that chemical science research can contribute to overcoming. By developing new biochemical tools to detect disease earlier, and more sensitive detection methods to monitor disease more closely, scientists will enable quicker diagnosis and more effective, less invasive monitoring of disease. Furthermore, equipped by modern synthetic methods and computational modeling based on structural biology, medicinal chemists are able to design potent, selective and safe molecules to interact with biological targets and turn them into drugs in collaboration with colleagues of other disciplines.
Roche and the 91AV are committed to improving the standards of healthcare for people worldwide and have collaborated to host a series of symposia in China on tackling medical issues through innovative and interdisciplinary chemical research.
This two-day scientific symposium will seek to highlight the latest chemistry and chemical biology research that could enable drug discovery and development. The packed programme, covering topics such as organic synthesis, medicinal chemistry, chemical and structural biology, immunology, drug discovery technologies, and epigenetics will consist of presentations, case studies, flash talks and poster sessions.
In addition, there are opportunities for the Roche Chinese Young Investigator Awardees to showcase their award-winning research work and to exchange ideas with experts and delegates from industry and academia.
We are confident that this event will provide excellent networking opportunities and will help to stimulate new research ideas and foster future collaborations between industry and academia, particularly in China.
On behalf of the Organising Committee - Dr Hong Shen, Roche and Professor Zhijie Liu, iHuman Institute, ShanghaiTech University, we look forward to welcoming you to attend what promises to be an exciting event in Shanghai.
Often the challenges to developing better healthcare lie in a lack of basic molecular-level understanding of the disease biology, a lack of sufficiently advanced tools and methods to detect and treat disease and to validate drug targets, or a lack of an arsenal of small and large molecules to engage drug targets thereby ameliorating diseases.
These are all challenges that chemical science research can contribute to overcoming. By developing new biochemical tools to detect disease earlier, and more sensitive detection methods to monitor disease more closely, scientists will enable quicker diagnosis and more effective, less invasive monitoring of disease. Furthermore, equipped by modern synthetic methods and computational modeling based on structural biology, medicinal chemists are able to design potent, selective and safe molecules to interact with biological targets and turn them into drugs in collaboration with colleagues of other disciplines.
Roche and the 91AV are committed to improving the standards of healthcare for people worldwide and have collaborated to host a series of symposia in China on tackling medical issues through innovative and interdisciplinary chemical research.
This two-day scientific symposium will seek to highlight the latest chemistry and chemical biology research that could enable drug discovery and development. The packed programme, covering topics such as organic synthesis, medicinal chemistry, chemical and structural biology, immunology, drug discovery technologies, and epigenetics will consist of presentations, case studies, flash talks and poster sessions.
In addition, there are opportunities for the Roche Chinese Young Investigator Awardees to showcase their award-winning research work and to exchange ideas with experts and delegates from industry and academia.
We are confident that this event will provide excellent networking opportunities and will help to stimulate new research ideas and foster future collaborations between industry and academia, particularly in China.
On behalf of the Organising Committee - Dr Hong Shen, Roche and Professor Zhijie Liu, iHuman Institute, ShanghaiTech University, we look forward to welcoming you to attend what promises to be an exciting event in Shanghai.
